Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 8/20 | 0.43 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.42 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.42 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.42 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9109256 | 0.88 | LMNA (0.41) | LMNALIPEPLAAT3PLAAT5PLAAT2 | |
| SCHEMBL9889670 | 0.86 | KDM4E (0.39) | P2RX3 | |
| SCHEMBL9106657 | 0.83 | PLAAT3 (0.42) | PLAAT3PLAAT5PLAAT2PLAAT4SCN9A | |
| SCHEMBL9101635 | 0.83 | PLA2G7 (0.40) | PLAAT3PLAAT5PLAAT2PLAAT4P2RX3 | |
| SCHEMBL9108674 | 0.81 | PLA2G7 (0.41) | LMNAP2RX3FFAR1 | |
| SCHEMBL15275211 | 0.79 | PLA2G7 (0.39) | P2RX3 | |
| SCHEMBL9889514 | 0.79 | HCAR2 (0.35) | P2RX3 | |
| SCHEMBL9904529 | 0.79 | PLA2G7 (0.42) | SCN9A | |
| SCHEMBL9108191 | 0.78 | PLA2G7 (0.58) | — | |
| SCHEMBL9105412 | 0.78 | HCAR2 (0.35) | RAB9AP2RX3FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142717-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142717-A1 | COMPOUNDS | LIPG, PLA2G1B, ENPP2 | LMNA 512/4885LIPE 74/4885PLAAT3 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.